RVTY · Revvity Inc.
AI read · Good for RVTY
The AI's read
More sales from pharmaceutical and biotech customers, along with rising interest in AI-related tools, helped drive the quarter. The company also expects to sell its China immunodiagnostics business next year, and its sales forecast sits just below analysts’ estimate. The stronger results and higher profit forecast point to improvement despite that small gap.